STRO (Sutro Biopharma) Total Stockholders Equity : $-25.81 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Total Stockholders Equity?

Sutro Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $-25.81 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sutro Biopharma's Book Value per Share for the quarter that ended in Mar. 2025 was $-0.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sutro Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2025 was -0.83.

Sutro Biopharma Total Stockholders Equity Historical Data

The historical data trend for Sutro Biopharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Total Stockholders Equity Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

332.05

252.56

217.05

149.65

44.60

Sutro Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															98.02	152.18	111.22	44.60	-25.81

Sutro Biopharma (NAS:STRO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sutro Biopharma's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-25.811	-	0)	/	84.349
	=	-0.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sutro Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.765	+	13.632)	/	-25.811
	=	-0.83

Sutro Biopharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Executives

Nicki Vasquez	officer: Chief Port. Strat & Alnce Ofcr	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Hans-peter Gerber	officer: Chief Scientific Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla	officer: Chief Business Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan	officer: Chief Tech Op Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman	officer: Chief Medical Officer	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell	director, officer: CEO & President	887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung	officer: Chief Commercial Officer	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam	officer: Chief Science Officer	PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick	officer: Chief People & Comm. Officer	NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek	director	C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121